{"id":"etoposide-carboplatin-melphalan-cisplatin-thiotepa","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Myelosuppression"},{"rate":"20-40%","effect":"Nausea and vomiting"},{"rate":"20-40%","effect":"Neutropenia"},{"rate":"10-30%","effect":"Anemia"},{"rate":"10-20%","effect":"Thrombocytopenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"These drugs are classified as alkylating agents, which form covalent bonds with DNA, causing cross-linking and DNA damage. This damage triggers cell death, particularly in rapidly dividing cancer cells. The specific mechanism of action varies slightly between each drug, but they all ultimately disrupt DNA replication and cell division.","oneSentence":"Etoposide, carboplatin, melphalan, cisplatin, and thiotepa are chemotherapeutic agents that work by interfering with DNA replication and cell division, ultimately leading to cell death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:59:56.453Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Small cell lung cancer"},{"name":"Non-small cell lung cancer"},{"name":"Ovarian cancer"},{"name":"Testicular cancer"},{"name":"Breast cancer"}]},"trialDetails":[{"nctId":"NCT06172296","phase":"PHASE3","title":"Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-04-19","conditions":"Ganglioneuroblastoma, Nodular, Neuroblastoma","enrollment":478},{"nctId":"NCT03126916","phase":"PHASE3","title":"Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2018-05-14","conditions":"Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular, Neuroblastoma","enrollment":750},{"nctId":"NCT03786783","phase":"PHASE2","title":"Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-03-04","conditions":"Ganglioneuroblastoma, High Risk Neuroblastoma","enrollment":42},{"nctId":"NCT04221035","phase":"PHASE3","title":"High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2019-11-05","conditions":"High-Risk Neuroblastoma, Patient With Insufficient Response Chemoimmunotherapy","enrollment":800},{"nctId":"NCT00567567","phase":"PHASE3","title":"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2007-11-05","conditions":"Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Recurrent Neuroblastoma","enrollment":665},{"nctId":"NCT02788201","phase":"PHASE2","title":"Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-03-27","conditions":"Urothelial Carcinoma, Bladder Cancer, Urinary Bladder Neoplasms","enrollment":8},{"nctId":"NCT02784015","phase":"PHASE2","title":"Response Based Treatment for Children With Unresectable Localized Soft Tissue Sarcoma","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2016-05","conditions":"Unresectable Localized Soft Tissue Sarcoma","enrollment":41},{"nctId":"NCT00017368","phase":"PHASE2","title":"Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Neuroblastoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2001-04","conditions":"Neuroblastoma","enrollment":42},{"nctId":"NCT00180791","phase":"PHASE2","title":"High Risk Primitive Neuroectodermal (PNET) Brain Tumors in Childhood","status":"UNKNOWN","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2002-07","conditions":"Medulloblastoma, Brain Tumors, Neuroectodermal Tumors, Primitive","enrollment":71}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Etoposide, carboplatin, melphalan, cisplatin, thiotepa","genericName":"Etoposide, carboplatin, melphalan, cisplatin, thiotepa","companyName":"Gustave Roussy, Cancer Campus, Grand Paris","companyId":"gustave-roussy-cancer-campus-grand-paris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Etoposide, carboplatin, melphalan, cisplatin, and thiotepa are chemotherapeutic agents that work by interfering with DNA replication and cell division, ultimately leading to cell death. Used for Small cell lung cancer, Non-small cell lung cancer, Ovarian cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}